Jiangsu Hengrui Medicine (SHA:600276, HKG:1276) subsidiaries Suzhou Shengdiya and Shanghai Shengdi received approval from China's medical products regulator to begin clinical trials for three drugs.
SHR-1826 targets solid tumors, adebelimab is indicated for extensive-stage small-cell lung cancer and bevacizumab is a VEGF-targeting monoclonal antibody, according to a filing with the Shanghai bourse.
Shanghai shares of the pharmaceutical company rose 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.